

NCC-Bio and GR Boston N. Announce Breakthrough in Overcoming KRAS Therapy Resistance, Pancreatic Cancer Awareness Month

Breakthrough in Overcoming KRAS Therapy Resistance During Pancreatic Cancer Awareness Month, November 2025.


BOSTON, MA, UNITED STATES,
November 1, 2025 /EINPresswire.com/

--

[NCC-Bio](#) and Global Bio Match Service Announce Breakthrough in Overcoming KRAS Therapy Resistance During Pancreatic Cancer Awareness Month

KN510/713 can Overcome Resistance to KRAS Inhibitors

NCC-Bio



- KRAS inhibition induces not only apoptosis but also autophagy via AMPK activation.
- Autophagy activates FAO, which promotes cell survival through ATP production.
- KRAS inhibition alongside FAO inhibition (KN510/713) leads to the 'Cell Death Storm'
- KN510/713 is the only available drug for FAO inhibition in Oncology Phase II Trial in the World. There is no severe adverse effect of KN510/713 during Ph I study.

KRAS inhibition alongside FAO inhibition (KN510713) leads to the 'Cell Death Storm'

In recognition of Pancreatic Cancer Awareness Month, NCC-Bio (National Cancer Center Bio Co., Ltd.) and Global Bio Match Service ([GBMS](#)) announced new findings from their joint KN510713

program — the world's first clinical-stage FAO inhibitor proven to prevent resistance to KRAS-targeted and cytotoxic therapies in solid tumors, including pancreatic cancer.

“

Together, we can make this the month the world learns how to turn resistance into response for pancreatic cancer.”

Warren Park

Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate below 12%. Despite advances with KRAS inhibitors such as sotorasib and adagrasib, patients almost universally develop

acquired drug resistance. KN510713 directly addresses this major unmet need.

“We discovered that all cancers — especially pancreatic — depend on fatty acid oxidation (FAO)

to survive treatment,” said Dr. Soo-Youl Kim, CEO of NCC-Bio and Principal Scientist at the National Cancer Center, Korea. “By inhibiting FAO with KN510713, we can completely block the energy source that cancer cells use to escape KRAS inhibition, leading to what we call a ‘Cell Death Storm’.”

Presented at the 7th RAS-Targeted Drug Development Summit (Boston, Sept. 2025), Dr. Kim’s research demonstrated that combining KN510713 with KRAS inhibitors such as sotorasib or adagrasib significantly enhanced cancer cell death and prevented the recurrence of resistant clones in preclinical and xenograft models.

In a completed Phase I clinical study in advanced solid tumors, KN510713 achieved a 41.7% stable-disease rate with no dose-limiting toxicity, validating its safety and mechanism of action. The upcoming Phase IIa clinical trial in pancreatic ductal adenocarcinoma (PDAC) is expected to begin in November 2025.

“KN510713 represents a paradigm shift for the entire KRAS therapeutic landscape,” said Dr. Warren Park, CEO of Global Bio Match Service. “Our goal this month is to bring this science to the attention of potential partners, investors, and patient advocates who share the mission to finally stop pancreatic cancer resistance.”

NCC-Bio and GBMS are actively seeking strategic co-development or licensing partners among leading oncology pharmaceutical companies for global advancement of KN510713, as well as philanthropic and venture supporters committed to transforming pancreatic cancer outcomes.

Warren Park
GR Boston North
+1 978-269-4198

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/859490547>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.